Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ib/II Study of IDH2 Inhibitor Enasidenib in Combination With BCL2 Inhibitor Venetoclax in Patients With IDH2-Mutated Myeloid Malignancies (ENAVEN-AML)

NCT04092179 is registered in ClinicalTrials.gov with University Health Network, Toronto as lead sponsor.

NCT NCT04092179
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04092179 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ib/II Study of IDH2 Inhibitor Enasidenib in Combination With BCL2 Inhibitor Venetoclax in Patients With IDH2-Mutated Myeloid Malignancies (ENAVEN-AML)
Lead sponsor
University Health Network, Toronto
Phase
Phase 1/2
Overall status
Terminated
Start date
November 5, 2020
Completion date
October 26, 2023
Enrollment
27 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, idh2 gene mutation, refractory cancer, relapsed cancer